Panoxyvir main project is to develop the first drug to treat and prevent rhinovirus infections in patients with chronic inflammatory lung diseases.
We are seeking funding for the operation to develop our lead program (POV-2017) to be the first approved treatment for rhinovirus infections in cystic fibrosis patients. We are also looking for partners interested in co-development of oxysterol-based drugs to treat other diseases induced by non-enveloped viruses.
POV-2017: Rhinovirus infections in Cystic Fibrosis patients
POV-2017 is the lead compound currently in pre-clinical testing for first line treatment of Rhinovirus infections in pediatric and adult Cystic Fibrosis patients. The compound has a well-defined regulatory path that will take advantage of the orphan drug designation for Cystic Fibrosis, a rare disease. Completion of IND-IMPD enabling studies and files for an inhalation product is estimated to take about 2 years and cost approximately 2 mln euros.
POV-2017: Rhinovirus infections in other patients
POV-2017 can be developed to treat upper respiratory infections caused by Rhinovirus in asthmatic patients to prevent exacerbations and and in general population to cure the common cold.
Panoxyvir technology has the potential to address other viral diseases, including rotavirus infections (a major cause of pediatric gastroenteritis) and papillomavirus infections (genital and oral lesions)